Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias.

Colloby SJ, McParland S, O'Brien JT, Attems J.

Brain. 2012 Sep;135(Pt 9):2798-808. doi: 10.1093/brain/aws211.

PMID:
22961551
2.

Formation and development of Lewy pathology: a critical update.

Jellinger KA.

J Neurol. 2009 Aug;256 Suppl 3:270-9. doi: 10.1007/s00415-009-5243-y. Review.

PMID:
19711116
3.

Molecular imaging of dementia.

Mori T, Maeda J, Shimada H, Higuchi M, Shinotoh H, Ueno S, Suhara T.

Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x. Review.

4.

Proteomic approach to studying Parkinson's disease.

Zhang J, Goodlett DR.

Mol Neurobiol. 2004 Jun;29(3):271-88. Review.

PMID:
15181239
5.

The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.

Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P.

Brain. 2011 Nov;134(Pt 11):3146-66. doi: 10.1093/brain/awr177. Epub 2011 Aug 2. Review.

PMID:
21810889
6.

PET studies of the striatal dopaminergic system in Parkinson's disease (PD).

Piccini P, Turjanski N, Brooks DJ.

J Neural Transm Suppl. 1995;45:123-31. Review.

PMID:
8748617
7.

Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.

Sarkar S, Raymick J, Imam S.

Int J Mol Sci. 2016 Jun 8;17(6). pii: E904. doi: 10.3390/ijms17060904. Review.

8.

[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies.

Walker Z, Cummings JL.

Alzheimers Dement. 2012 Jan;8(1):74-83. doi: 10.1016/j.jalz.2011.08.003. Epub 2011 Oct 22. Review.

PMID:
22024052
9.

Dopamine receptor mapping with PET imaging in Parkinson's disease.

Niccolini F, Su P, Politis M.

J Neurol. 2014 Dec;261(12):2251-63. doi: 10.1007/s00415-014-7302-2. Epub 2014 Mar 15. Review.

PMID:
24627109
10.

Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.

Booij J, Berendse HW.

J Neurol Sci. 2011 Nov 15;310(1-2):40-3. doi: 10.1016/j.jns.2011.07.029. Epub 2011 Aug 15. Review.

PMID:
21840542
11.

The cholinergic system and Parkinson disease.

Bohnen NI, Albin RL.

Behav Brain Res. 2011 Aug 10;221(2):564-73. doi: 10.1016/j.bbr.2009.12.048. Epub 2010 Jan 7. Review.

12.

Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies.

McAllum EJ, Finkelstein DI.

J Mol Neurosci. 2016 Nov;60(3):279-288. Epub 2016 Aug 8. Review.

PMID:
27498879
13.

Imaging beyond the striatonigral dopaminergic system in Parkinson's disease.

Giza E, Gotzamani-Psarrakou A, Bostantjopoulou S.

Hell J Nucl Med. 2012 Sep-Dec;15(3):224-32. doi: 10.1967/s002449910058. Epub 2012 Oct 25. Review.

PMID:
23106055
14.

Dopaminergic imaging: clinical utility now and in the future.

Walker Z, Rodda J.

Int Psychogeriatr. 2011 Sep;23 Suppl 2:S32-40. doi: 10.1017/S1041610211000883. Review.

PMID:
21843378
15.

The role of biomarkers and imaging in Parkinson's disease.

Algarni MA, Stoessl AJ.

Expert Rev Neurother. 2016;16(2):187-203. doi: 10.1586/14737175.2016.1135056. Epub 2016 Feb 1. Review.

PMID:
26829357
16.

The molecular basis of dopaminergic brain imaging in Parkinson's disease.

Seibyl J, Russell D, Jennings D, Marek K.

Q J Nucl Med Mol Imaging. 2012 Feb;56(1):4-16. Review.

PMID:
22460156
17.

Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Overk CR, Masliah E.

Biochem Pharmacol. 2014 Apr 15;88(4):508-16. doi: 10.1016/j.bcp.2014.01.015. Epub 2014 Jan 21. Review.

18.

[Brain SPECT in Lewy body dementia].

Farid K, Volpe-Gillot L, Caillat-Vigneron N.

Presse Med. 2011 Jun;40(6):581-6. doi: 10.1016/j.lpm.2011.01.019. Epub 2011 Mar 3. Review. French.

PMID:
21376506
19.

Impaired intracellular trafficking defines early Parkinson's disease.

Hunn BH, Cragg SJ, Bolam JP, Spillantini MG, Wade-Martins R.

Trends Neurosci. 2015 Mar;38(3):178-88. doi: 10.1016/j.tins.2014.12.009. Epub 2015 Jan 29. Review.

20.

Review: disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias.

Gong Y, Lippa CF.

Am J Alzheimers Dis Other Demen. 2010 Nov;25(7):547-55. doi: 10.1177/1533317510382893. Epub 2010 Sep 21. Review.

Supplemental Content

Support Center